Induction of apoptosis by Eurycoma longifolia Jack extracts

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2205-2213

  Tee, Thiam Tsui ^a   Azimahtol, Hawariah Lope Pihie ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Antiproliferative effect; Apoptosis; Bcl 2; Eurycoma longifolia; MCF 7

Indexed keywords

DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA FRAGMENT; EURYCOMA LONGIFOLIA EXTRACT; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BIOASSAY; CELL PROLIFERATION; CHROMATOGRAPHY; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; EURYCOMA; FRACTIONATION; HUMAN; HUMAN CELL; NICK END LABELING; PLANT ROOT; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; EURYCOMA; HUMANS; INHIBITORY CONCENTRATION 50; PLANT EXTRACTS; PLANT ROOTS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 21344444795     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Abdul Rahman AS, Sim Yap MM, Md. Shakaff AY, Ahmad MN, Dahari Z, Ismail Z and Hitam MS: A microcontroller-based taste sensing system for the verification of Eurycoma longifolia. Sens Actuators B 101: 191-198, 2004.
2. Kuo PC, Damu AG, Lee KH and Wu TS: Cytotoxic and antimalarial constituents from the roots of Eurycoma longifolia. Bioorg Med Chem 12: 537-544, 2004.
3. Osman A, Jordan B, Lessard PA, Muhammad N, Haron MR, Riffin NM, Sinskey AJ, Rha CK and Housman DE: Genetic diversity of Eurycoma longifolia inferred from single nucleotide polymorphisms. Plant Physiol 131: 1294-1301, 2003.
4. Darise M, Kohda H, Mizutani K and Tanaka O: Eurycomanone and eurycomanol, quassinoids from the roots of Eurycoma longifolia. Phytochemistry 21: 2091-2093, 1982.
5. Kardono LBS, Angerhofer CK, Tsauri S, Padmawinata K, Pezzuto JM and Kinghorn AD: Cytotoxic and antimalarial constituents of the roots of Eurycoma longifolia. J Nat Prod 54: 1360-1367, 1991.
6. Thoi LV and Suong NN: Constituents of Eurycoma longifolia Jack. J Org Chem 35: 1104-1109, 1970.
7. Choo CY and Chan KL: High performance liquid chromatography analysis of canthinone alkaloids from Eurycoma longifolia. Planta Med 68: 382-384, 2002.
8. Chan KL, Choo CY, Morita H and Itokawa H: High performance liquid in phytochemical analysis of Eurycoma longifolia. Planta Med 64: 741-745, 1998.
9. Ang HH, Ngai TH and Tan TH: Effects of Eurycoma longifolia Jack on sexual qualities in middle aged male rats. Phytomed 10: 590-593, 2003.
10. Ang HH and Cheang HS: Effects of Eurycoma longifolia Jack on laevator ani muscle in both uncastrated and testosterone-stimulated castrated intact male rats. Arch Pharm Res 24: 437-440, 2001.
11. Chan KL, Choo CY, Abdullah NR and Ismail Z: Antiplasmodial studies of Eurycoma longifolia Jack using the lactate dehydrogenase assay of Plasmodium falciparum. J Ethnopharmacol 92: 223-227, 2004.
12. Jiwajinda S, Santisopasri V, Murakami A, Kawanaka M, Kawanaka H, Gasquet M, Eilas R, Balansard G and Ohigashi H: In vitro anti-tumor promoting and anti-parasitic activities of the quassinoids from Eurycoma longifolia, a medicinal plant in Southeast Asia. J Ethnopharmacol 82: 55-58, 2002.
13. Ang HH, Hitotsuyanagi Y, Fukaya H and Takeya K: Quassinoids from Eurycoma longifolia. Phytochemistry 59: 833-837, 2002.
14. Chan KL and Choo CY: The toxicity of some quassinoids from Eurycoma longifolia. Planta Med 68: 662-664, 2002.
15. Jiwajinda S, Santisopasri V, Murakami A, Hirai N and Ohigashi H: Quassinoids from Eurycoma longifolia as plant growth inhibitors. Phytochemistry 58: 959-962, 2001.
16. Ang HH, Hitotsuyanagi Y and Takeya K: Eurycolactones A-C, novel quassinoids from Eurycoma longifolia. Tetrahedron Lett 41: 6849-6853, 2000.
17. Ang HH, Chan KL and Mak JW: Effect of 7-day daily replacement of culture medium containing Eurycoma longifolia Jack constituents on the Malaysian Plasmodium falciparum isolates. J Ethnopharmacol 49: 171-175, 1995.
18. Morita H, Kishi E, Takeya K, Itokawa H and Iitaka Y: Squalene derivatives from Eurycoma longifolia. Phytochemistry 34: 765-771, 1993.
19. Morita H, Kishi E, Takeya K, Itokawa H and Tanaka O: New quassinoids from the roots of Eurycoma longifolia. Chemi Lett 749-752, 1990.
20. Bates RB, Linz GS and Tempesta MS: Structures of Eurycomalactone and related terpenoids. J Org Chem 49: 2820-2821, 1984.
21. 18 - Quassinoids from Eurycoma longifolia and revised structure of Eurycomalactone (X-ray analysis). Tetrahedron Lett 23: 5159-5162, 1982.
22. Tan S, Yuen KH and Chan KL: HPLC analysis of plasma 9-methoxycanthin-6- one from Eurycoma longifolia and its application in a bioavailability/ pharmacokinetic study. Planta Med 68: 355-358, 2002.
23. Mitsunaga K, Koike K, Tanaka T, Ohkawa Y, Kobayashi Y, Sawaguchi T and Ohmoto T: Canthin-6-one alkaloids from Eurycoma longifolia. Phytochemistry 35: 799-802, 1994.
24. Morita H, Kishi E, Takeya K and Itokawa H: Biphenylneolignans from wood of Eurycoma longifolia. Phytochemistry 31: 3993-3995, 1992.
25. Ang HH and Cheang HS: Studies on the anxiolytic activity of Eurycoma longifolia Jack roots in mice. Jpn J Pharmacol 79: 497-500, 1999.
26. Kinghorn AD, Farnsworth NR, Soejarto DD, Cordell GA, Pezzuto JM, Udeani GO, Wani MC, Wall ME, Navarro HA, Kramer RA, Menendez AT, Fairchild CR, Lane KE, Forenza S, Vyas DM, Lam KS and Shu YZ: Novel strategies for the discovery of plant-derived anticancer agents. Pure Appl Chem 71: 1611-1618, 1999.
27. Ueda JY, Tezuka Y, Banskota AH, Tran QL, Tran QK, Harimaya Y, Saiki I and Kadota S: Antiproliferative activity of Vietnamese medicinal plants. Biol Pharm Bull 25: 753-760, 2002.
28. Lian Z, Niwa K, Gao J, Tagami K, Mori H and Tamaya T: Association of cellular apoptosis with anti-tumor effects of the Chinese herbal complex in endocrine-resistant cancer cell line. Cancer Detect Prevent 27: 147-154, 2003.
29. Gosslau A and Chen KY: Nutraceuticals, apoptosis, and disease prevention. Nutrition 20: 95-102, 2004.
30. Huang ST, Yang RC, Yang LJ, Lee PN and Pang JHS: Phyllanthus urinaria triggers the apoptosis and Bcl-2 downregulation in Lewis lung carcinoma cells. Life Sci 72: 1705-1716, 2003.
31. Bohm I and Schild H: Apoptosis: the complex scenario for a silent cell death. Mol Imag Biol 5: 2-14, 2003.
32. Reed JC: Apoptosis-regulating proteins as target for drug discovery. Trends Mol Med 7: 314-319, 2001.
33. Zornig M, Hueber AO, Baum W and Evan G: Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551: F1-F37, 2001.
34. Teoh PL and Azimahtol Hawariah LP: Effects of Styrylpyrone derivative (SPD) on expression of Bcl-2 and Bax genes in human ovarian carcinoma cell line, Caov-3. Malays Appl Biol 28: 107-111, 1999.
35. Kiechle FL and Zhang X: Apoptosis: biochemical aspects and clinical implications. Clinica Chimica Acta 326: 27-45, 2002.
36. Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis 21: 485-495, 2000.
37. Bold RJ, Termuhlen PM and McConkey DJ: Apoptosis, cancer and cancer therapy. Surg Oncol 6: 133-142, 1997.
38. Makin G and Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 11: S22-S26, 2001.
39. Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. The Lancet 4: 721-729, 2003.
40. Gross A, McDonnell JM and Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
41. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701-4714, 1993.
42. Schendel, SL, Xie Z, Montal MO, Matsuyama S, Montal M and Reed JC: Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 94: 5113-5118, 1997.
43. Amin F, Bowen ID, Szegedi Z, Mihalik R and Szende B: Apoptotic and non-apoptotic modes of programmed cell death in MCF-7 human breast carcinoma cells. Cell Biol Int 24: 253-260, 2000.
44. Lin L and Hwang PL: Antiproliferative effects of oxygenated sterols: positive correlation with binding affinities for the antiestrogen-binding sites. Biochim Biophys Acta 1082: 177-184, 1991.
45. Lee ATC and Azimahtol Hawariah LP: Styrylpyrone derivative induces apoptosis through the up-regulation of Bax in the human breast cancer cell line MCF-7. J Biochem Mol Biol 36: 269-274, 2003.
46. Kamuhabwa A, Nshimo C and Witte PD: Cytotoxicity of some medicinal plant extracts used in Tanzanian traditional medicine. J Ethnopharmacol 70: 143-149, 2000.
47. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF and Fujii T: Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 274: 37461-37466, 1999.
48. Powell CB, Fung P, Jackson J, Dall'Era J, Lewkowicz D, Cohen I and McCune KS: Aqueous extract of herba Scutellaria barbatae, a Chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. Gynecol Oncol 91: 332-340, 2003.
49. L. Exp Cell Res 298: 329-338, 2004.
50. L, without alteration of p53 protein levels. Clin Cancer Res 5: 2971-2977, 1999.
51. Yang, JH, Feng F, Qian H and Cheng H: Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide. The Breast 13: 227-231, 2004.
52. Pezzuto JM: Plant-derived anticancer agents. Biochem Pharmacol 53: 121-133, 1997.
53. Lee ATC, Azimahtol HLP and Tan AN: Styrylpyrone derivative (SPD) induces apoptosis in a caspase-7-dependent manner in the human breast cancer cell line MCF-7. Cancer Cell Int 3: 16-23, 2003.
54. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chomoresistance in hematologic malignancies. Semin Hematol 34: 9-19, 1997.
55. Heiser D, Labi V, Erlacher M and Villunger A: The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol 39: 1125-1135, 2004.
56. Buffalo DD, Biroccio A, Trisciuoglio D, Bruno T, Floridi A, Aquino A and Zupi G: Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Eur J Cancer 38: 2455-2462, 2002.
57. Adams JM and Cory S: The bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
58. Bruckheimer EM, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N and McDonnell TJ: Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene 19: 5251-5258, 2000.
59. Webb A, Cunningham D, Cotter F, Clarke PA, Stefano FD, Ross P, Corbo M and Dziewanowska Z: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. The Lancet 349: 1137-1141, 1997.
60. Gleave ME, Miayake H, Goldie J, Nelson C and Tolcher A: Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 54: 36-46, 1999.
61. Linjawi A, Kontogiannea M, Halwani F, Edwardes M and Meterissian S: Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 198: 83-90, 2004.
62. Chang CNJ: A review of breast cancer chemoprevention. Biomed Pharmacother 52: 133-136, 1998.
63. Riva L, Coradini D, Fronzo GD, Feo VD, Tommasi ND, Simone FD and Pizza C: The antiproliferative effects of Uncaria tomentosa extracts and fractions on the growth of breast cancer cell line. Anticancer Res 21: 2457-2462, 2001.